BR112023010885A2 - Terapia de combinação de anti-cd19 - Google Patents

Terapia de combinação de anti-cd19

Info

Publication number
BR112023010885A2
BR112023010885A2 BR112023010885A BR112023010885A BR112023010885A2 BR 112023010885 A2 BR112023010885 A2 BR 112023010885A2 BR 112023010885 A BR112023010885 A BR 112023010885A BR 112023010885 A BR112023010885 A BR 112023010885A BR 112023010885 A2 BR112023010885 A2 BR 112023010885A2
Authority
BR
Brazil
Prior art keywords
antibody
combination therapy
lenalidomide
chop
treatment
Prior art date
Application number
BR112023010885A
Other languages
English (en)
Inventor
Francis Seguy
Günter Fingerle-Rowson
Oliver Manzke
Wolfram Brugger
Original Assignee
Incyte Corp
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp, Morphosys Ag filed Critical Incyte Corp
Publication of BR112023010885A2 publication Critical patent/BR112023010885A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

terapia de combinação de anti-cd19. a presente invenção refere-se a uma combinação terapêutica de um anticorpo anti-cd19 e um r-chop ou um anticorpo anti-cd19, uma lenalidomida e um r-chop para uso no tratamento de linfoma difuso de grandes células b. a presente divulgação também é direcionada a uma combinação terapêutica de um anticorpo anti-cd19, uma lenalidomida e um rituximabe para uso no tratamento de linfoma não hodgkin, leucemia linfocítica crônica ou leucemia linfoblástica aguda.
BR112023010885A 2020-12-04 2021-12-03 Terapia de combinação de anti-cd19 BR112023010885A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20211862 2020-12-04
EP21158806 2021-02-23
EP21163696 2021-03-19
EP21172671 2021-05-07
EP21177336 2021-06-02
EP21205447 2021-10-29
PCT/EP2021/084133 WO2022117799A2 (en) 2020-12-04 2021-12-03 Anti-cd19 combination therapy

Publications (1)

Publication Number Publication Date
BR112023010885A2 true BR112023010885A2 (pt) 2023-10-03

Family

ID=78821967

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023010885A BR112023010885A2 (pt) 2020-12-04 2021-12-03 Terapia de combinação de anti-cd19

Country Status (12)

Country Link
US (1) US20220184208A1 (pt)
EP (1) EP4255480A2 (pt)
JP (1) JP2023551559A (pt)
KR (1) KR20230131464A (pt)
AU (1) AU2021391623A1 (pt)
BR (1) BR112023010885A2 (pt)
CA (1) CA3204063A1 (pt)
CL (1) CL2023001581A1 (pt)
IL (1) IL303384A (pt)
MX (1) MX2023006538A (pt)
TW (1) TW202237184A (pt)
WO (1) WO2022117799A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210130460A1 (en) * 2019-10-31 2021-05-06 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
WO2023118395A1 (en) * 2021-12-22 2023-06-29 Morphosys Ag Treatment paradigm for an anti-cd19 antibody therapy
WO2023240228A1 (en) * 2022-06-10 2023-12-14 Pfizer Inc. Combination therapy comprising sirp alpha fusion protein and anti-cd19 antibody for treatment of cancer
WO2023245106A1 (en) * 2022-06-16 2023-12-21 Abbvie Biotherapeutics Inc. Anti-cd19 antibody drug conjugates
WO2024037594A1 (en) * 2022-08-19 2024-02-22 Beijing Innocare Pharma Tech Co., Ltd. Combination treatment with orelabrutinib and tafasitamab

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
AU2006262232A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. CD19 antibodies and their uses
EA016429B1 (ru) 2005-12-30 2012-04-30 Мерк Патент Гмбх Антитела против cd19 с пониженной иммуногенностью
SI2059536T1 (sl) 2006-08-14 2014-06-30 Xencor, Inc. Optimirana protitelesa, ki ciljajo CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
EP2211904B1 (en) 2007-10-19 2016-08-17 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
ES2563439T5 (es) * 2010-10-27 2022-02-04 Amgen Res Munich Gmbh Medios y métodos para tratar LDCBG
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
IL263103B2 (en) * 2016-05-30 2023-10-01 Morphosys Ag Methods for predicting the therapeutic benefit of anti-CD19 therapy in patients
US20200230254A1 (en) * 2016-07-22 2020-07-23 Seattle Genetics, Inc. Combination therapy using a cd19-adc and rchp
CA3138707A1 (en) * 2019-05-03 2020-11-12 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy

Also Published As

Publication number Publication date
TW202237184A (zh) 2022-10-01
EP4255480A2 (en) 2023-10-11
CA3204063A1 (en) 2022-06-09
US20220184208A1 (en) 2022-06-16
CL2023001581A1 (es) 2023-12-15
MX2023006538A (es) 2023-08-08
AU2021391623A1 (en) 2023-06-29
WO2022117799A2 (en) 2022-06-09
JP2023551559A (ja) 2023-12-08
KR20230131464A (ko) 2023-09-13
WO2022117799A3 (en) 2022-07-14
IL303384A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
BR112023010885A2 (pt) Terapia de combinação de anti-cd19
CY1121331T1 (el) Αγωγη αιματολογικων κακοηθειων me αντισωμα anti-cxcr4
BRPI0411276A (pt) métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
PH12017501368A1 (en) Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms
TN2015000452A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
DE69830570D1 (de) Immuntherapie der b-zell bösartige krankheiten mittels anti-cd22 antikörper
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
BR112016025437A2 (pt) combinação de lenalidomida e construto de polipeptídeo, e usos destes
CR11243A (es) Anticuerpos humanos contra cd20 humano y metodo para utilizarlos
BR112018074619A2 (pt) uso de um anticorpo anti-pd-1 em combinação com um anticorpo anti-cd30 em tratamento com câncer
MX2020007401A (es) Novedosa combinacion y uso de anticuerpos.
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
WO2015116729A3 (en) Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders
CY1124648T1 (el) Συνδυασμος αντισωματος αντι- cd19 με εναν αναστολεα bcl-2 και χρησεις αυτου
MX2022011258A (es) Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas.
MX2021013825A (es) Procedimientos de uso de inmunoconjugados anti-cd79b para tratar el linfoma folicular.
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
AU2024202109A1 (en) Combinations and uses thereof
BRPI0412629A (pt) método de tratamento de disfunção ocular em mamìferos
MX2022011800A (es) Metodos para tratar mieloma multiple.
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
BR112022011052A2 (pt) Tratamento para leucemia mieloide aguda ou síndrome mielodisplásica
BR112022007216A2 (pt) Métodos para tratamento de linfoma difuso, kit e imunoconjugado
BR112021016923A2 (pt) Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits